Five things for pharma marketers to know: Wednesday, January 25, 2017

Share this content:

1. Novartis said it expects slow growth in 2017 as it spins off its eye care business Alcon, which saw flat fourth-quarter sales. The drugmaker also announced that Erelzi, its biosimilar copy of Amgen's psoriasis drug Enbrel, will not go on the market until 2018 due to a patent protection challenge by Amgen. (Reuters)

2. Biotech Actelion's pulmonary arterial hypertension drug Opsumit missed the primary endpoint of  a phase-III trial. The setback is unlikely to impact a potential deal with Johnson & Johnson, however, according to analysts. (PMLive)

3. HHS nominee Tom Price denied conflict of interest claims concerning his investments in pharmaceutical companies' stocks. He also answered questions about what a replacement for the Affordable Care Act would look like at a Senate confirmation hearing. (NYT)

4. Roche said it received a priority review from the FDA for its rheumatoid arthritis drug Actemra to treat giant cell arteritis, a chronic autoimmune condition. (Reuters)

5. Philips is in talks with the Department of Justice about a “civil matter” related to its heart defibrillators. The FDA previously raised reliability concerns about the defibrillators. The talks have not led to a lawsuit, the company's CEO said. (Bloomberg)

Share this content:
Scroll down to see the next article